Evaluation of the Pharmaceutical Industry Investment Program
AbstractWith the expiry of the Pharmaceutical Industry Investment Program (PIIP) in 2004, the Commission was asked to conduct an evaluation of the program’s rationale, effectiveness and efficiency. The study commenced in August 2002. The Commission found that this assistance scheme had significant deficiencies and should not be renewed in its current form when it expires.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
Bibliographic InfoPaper provided by EconWPA in its series Microeconomics with number 0305001.
Date of creation: 01 May 2003
Date of revision:
Note: Type of Document - PDF; prepared on IBM PC; to print on HP;
Contact details of provider:
Web page: http://184.108.40.206
Clause (f); Drugs; Generic drugs; PBAC; PBPA; Pharmaceutical Benefits Advisory Committee; Pharmaceutical Benefits Pricing Authority’s; Pharmaceutical Benefits Scheme; Pharmaceutical Industry; Pharmaceutical Industry Investment Program; PIIP; R&D; Research and Deveoppment; Taxation;
Find related papers by JEL classification:
- A - General Economics and Teaching
This paper has been announced in the following NEP Reports:
- NEP-ALL-2003-05-08 (All new papers)
- NEP-COM-2003-05-08 (Industrial Competition)
- NEP-HEA-2003-05-08 (Health Economics)
You can help add them by filling out this form.
CitEc Project, subscribe to its RSS feed for this item.
Cited by:reading list or among the top items on IDEAS.Access and download statisticsgeneral information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (EconWPA).
If references are entirely missing, you can add them using this form.